Smith Cynthia
SEC-identified person · CIK 1609480 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Spero Therapeutics, Inc. SPRO | Director | filed 2019–2026 |
| Agios Pharmaceuticals, INC. AGIO | Director | filed 2022–2026 |
| Akebia Therapeutics, Inc. AKBA | Director | filed 2018–2026 |
| Protara Therapeutics, Inc. TARA | Director | filed 2021–2026 |
| Tvardi Therapeutics, Inc. TVRD | Director | filed 2025–2026 |
| Dicerna Pharmaceuticals Inc DRNA | Director | filed 2018–2021 |
| Nivalis Therapeutics, Inc. NVLS | Director | filed 2016–2016 |
| ZS Pharma, Inc. ZSPH | See Remarks | filed 2014–2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.